momo-T/FIF Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: quidditch who wrote (1666)	1/21/2005 10:08:28 AM
From: scaram(o)uche	Read Replies (2) of 12215

from Looney Brothers.... 09:48 ARIA Ariad Pharm highlighted as smallcap biotech pick; $17 tgt - Lehman (6.51 +0.16) Lehman highlights ARIA with $17 tgt as one of the few co's in the oncology space to have made significant advances in clinical development since ASCO 2004 and should have significant data at ASCO 2005 to drive investor interest. With 2 phase II trials for mTOR inhibitor AP23573 enrolling rapidly in sarcoma and various hematologic malignancies, firm expects significant data flow from ARIA in 2005 both at ASCO in May and later in the year at EORTC and ASH. Providing upside beyond a trade into ASCO is the potential for favorable resolution to NFKB litigation with LLY over Xigris and Evista, as well as the potential for resurrection of the Src/Abl platform. In addition to ARIA, firm also expects TELK and OSIP to be included in a small ASCA basket.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next